Propranolol Inhibition of β-Adrenergic Receptor Does Not Suppress Pathologic Neovascularization in Oxygen-Induced Retinopathy

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation

Published Version
doi:10.1167/iovs.12-9691

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:30754352

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
**Propranolol Inhibition of β-Adrenergic Receptor Does Not Suppress Pathologic Neovascularization in Oxygen-Induced Retinopathy**

**Jing Chen,1 Jean-Sebastian Joyal,1 Cohman J. Hatton,1 Aimee M. Juan,1 Dorothy T. Pei,1 Christian G. Hurst,1 Dan Xu,1 Andreas Stahl,1,2 Ann Hellstrom,2 and Lois E. H. Smith1**

**PURPOSE.** Retinopathy of prematurity (ROP) is a leading cause of blindness in children and is, in its most severe form, characterized by uncontrolled growth of vision-threatening pathologic vessels. Propranolol, a nonselective β-adrenergic receptor blocker, was reported to protect against pathologic retinal neovascularization in a mouse model of oxygen-induced retinopathy (OIR). Based on this single animal study using nonstandard evaluation of retinopathy, clinical trials are currently ongoing to evaluate propranolol treatment in stage 2 ROP patients who tend to experience spontaneous disease regression and are at low risk of blindness. Because these ROP patients are vulnerable premature infants who are still in a fragile state of incomplete development, the efficacy of propranolol treatment in retinopathy needs to be evaluated thoroughly in preclinical animal models of retinopathy and potential benefits weighed against potential adverse effects.

**METHODS.** Retinopathy was induced by exposing neonatal mice to 75% oxygen from postnatal day (P) 7 to P12. Three routes of propranolol treatment were assessed from P12 to P16: oral gavage, intraperitoneal injection, or subcutaneous injection, with doses varying between 2 and 60 mg/kg/day. At P17, retinal flatmounts were stained with isolectin and quantified with a standard protocol to measure vasooobliteration and pathologic neovascularization. Retinal gene expression was analyzed with qRT-PCR using RNA isolated from retinas of control and propranolol-treated pups.

**RESULTS.** None of the treatment approaches at any dose of propranolol (up to 60 mg/kg/day) were effective in preventing the development of retinopathy in a mouse model of OIR, evaluated using standard techniques. Propranolol treatment also did not change retinal expression of angiogenic factors including vascular endothelial growth factor.

**CONCLUSIONS.** Propranolol treatment via three routes and up to 30 times the standard human dose failed to suppress retinopathy development in mice. These data bring into question whether propranolol through inhibition of β-adrenergic receptors is an appropriate therapeutic approach for treating ROP (Invest Ophthalmol Vis Sci. 2012;53:2968–2977) DOI:10.1167/iovs.12-9691

Retinopathy of prematurity (ROP) is a leading cause of blindness in children, affecting approximately 16,000 U.S. infants per year.1 ROP starts with an initial phase of delayed vascular growth resulting in retinal ischemia. Subsequent hypoxia then induces increased secretion of angiogenic factors such as vascular endothelial growth factor (VEGF) to stimulate growth of vision-threatening pathologic vessels.2 Current ablation therapies are invasive, costly, and only partially effective, reducing blindness by only approximately 25%. Furthermore, ablation treatment does not increase the number of patients with normal vision. Extensive research has been carried out in search of safe, effective, and inexpensive treatment options for ROP.

Propranolol, a nonselective β-adrenergic receptor blocker, has been serendipitously identified as a new and promising treatment for infantile hemangioma (IH),3 a benign vascular tumor. In 2008, an infant with cardiac problems and an incidental facial hemangioma was treated with a β-adrenergic blocker, and the hemangioma regressed.4 Consequently, propranolol has been used over the past few years at doses up to about 2 mg/kg/day to treat hemangiomas with considerable success in causing tumor regression.4–6 However, some patients have suffered severe adverse effects including hypoglycemia.7 To date there are no reports of controlled prospective trials of safety and efficacy of propranolol. In addition, the mechanism of propranolol’s action in hemangiomas is not established; hypotheses include vasoconstriction, suppression of angiogenic factors, and increased endothelial cell (EC) apoptosis.3

Interestingly, it was reported that in a mouse model of oxygen-induced ROP (OIR) that propranolol was effective in protecting against pathologic retinal neovascularization (NV) and blood barrier breakdown, presumably via suppression of β3-adrenergoreceptor induced VEGF overexpression.8 However,
this work has not been independently verified, which is particularly important because this study used nonstandard techniques to quantify the severity of retinopathy. Based on this publication, a clinical trial (PROP-ROP) is currently ongoing to evaluate propranolol treatment in all stage 2 ROP patients, despite clinical evidence that most infants with stage 2 ROP regress spontaneously. Thus propranolol could be administered to many infants, most of whom are not at risk of disease progression or blindness. Because of the fragility of premature infants, with ongoing development of the central nervous system, great care must be taken to carefully weigh potential benefits of propranolol, if any, against the potential neurologic or systemic adverse effects. Therefore the efficacy of propranolol as a novel treatment in retinopathy needs to be evaluated thoroughly in preclinical models of retinopathy, which is the focus of this study.

Here we evaluated the use of propranolol in OIR using three routes of administration (oral gavage, intraperitoneal [IP] or subcutaneous [SC] injection), with doses ranging from the standard human dose for treating hemangiomias (2 mg/kg/day) to up to 30 times greater (60 mg/kg/day). Retinopathy was induced by exposing mouse pups to 75% oxygen from postnatal day (P) 7 to P12. The mouse model of OIR mimics ROP in humans by generating oxygen-induced vessel loss during the first phase (P7 to P12), followed by retinal ischemia and hypoxia-induced pathologic NV after mice are returned to room air (P12–P17). Our results show that propranolol and hypoxia-induced pathologic NV after mice are returned to room air. To assess the effect of propranolol in OIR, mice were treated with oral gavage, IP injection, or SC injection, with doses ranging from 2 up to 60 mg/kg/day. Mice were treated either daily (for most experiments), or three times per day (for SC 60 mg/kg/day). Propranolol (catalog no. P0884; Sigma-Aldrich) was solubilized in citric acid buffer (pH 5) as concentrated stock and diluted in sterile saline immediately before use.

### Methods

#### Animals

These studies adhered to the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Children's Hospital Boston Animal Care and Use Committee. For this study, traditional inbred mice (129S6/SvEvTac; Taconic Farms, Inc., Hudson, NY) were used.

#### Oxygen-Induced Retinopathy and Propranolol Treatment

To induce pathologic NV in the retina, mouse pups with their nursing mother were exposed to 75% oxygen from P7 to P12 followed by room air. To assess the effect of propranolol in OIR, mice were treated with propranolol via three routes of intervention from P12 to P16: oral gavage, IP injection, or SC injection, with doses ranging from 2 up to 60 mg/kg/day. Mice were treated either daily (for most experiments), or three times per day (for SC 60 mg/kg/day). Propranolol (catalog no. P0884; Sigma-Aldrich) was solubilized in citric acid buffer (pH 5) as concentrated stock and diluted in sterile saline immediately before use.

#### Retina Dissection, Staining, and Imaging

Pathologic retinal NV was evaluated at P17, when the neovascular response is greatest following oxygen-induced retinopathy. Mice were anesthetized with tribromoethanol (Avertin; Sigma-Aldrich) and euthanized by cervical dislocation. Eyes were enucleated and fixed in 4% paraformaldehyde for 1 hour at room temperature, followed by isolation and subsequent dissection of the retina. To visualize vessels, retinas were stained overnight at room temperature with fluoresceinated *Griffonia Bandeiraea Simplicifolia* (Isoslectin B4, Alexa Fluor 594 conjugated 1:100 dilution; Invitrogen, Carlsbad, CA) in 1 mM CaCl2 in PBS. Following 2 hours of washes in PBS, retinas were whole-mounted onto microscopische slides (Superfrost Plus, 12-550-15, Thermo Fisher Scientific, Waltham, MA), with the photoreceptor side down and embedded in antifade reagent (SlowFade, S2828; Invitrogen). Images of whole-mounted retina were taken at 50 magnification on a high-level materials microscope (AxioObserver.Z1 microscope; Carl Zeiss Microscopy) and merged using commercial software (AxioVision 4.6.3.0; Carl Zeiss) to produce an image of the entire retina.

### Propranolol Inhibition of β-Adrenergic Receptor

Propranolol inhibition of β-adrenergic receptor 2969

### Retinal RNA Isolation and Gene Expression Analysis

Total RNA was extracted from the retinas of six mice, each from a different litter; the RNA was pooled to reduce biologic variability (n = 6). Retinas from each time point were lysed and homogenized with a mortar and pestle and filtered through a biopolymer-shredding system (QiShredder columns; Qiagen, Chatsworth, MD). RNA was then extracted according to the manufacturer's instructions (RNeasy Kit; Qiagen). To generate cDNA, 1 μg total RNA was treated with a DNase treatment and removal reagent (DNase I; Ambion Inc., Austin, TX) to remove any contaminating genomic DNA, and then reverse transcribed using random hexamers and a commercial reverse transcriptase kit (SuperScript III; ). All cDNA samples were aliquoted and stored at −80°C. RT-PCR primers were designed using a public database for PCR primers (Primer Bank and Primer BLAST [Basic Local Alignment Search Tool] software; National Center for Biotechnology Information [NCBI]). The sequences of primers are *ADRB1* (F: 5′-GGT ATG GGA TTA CTG GTG GTG-3′, R: 5′-GCA AAC TCT GGT AGC GAA AGG-3′), *ADRB2* (F: 5′-GAC AGC GCC TTC TTT GTG C-3′, R: 5′-CGT CCC GTT CCT GAG TGA C-3′), *ADRB3* (F: 5′-CTC CCT GGT GTC TGG TGG GA-3′, R: 5′-GTT GGT TAT GGT CAT TGG TGT C-3′), *VEGFA* (F: 5′-GCA CAT AGA GAG AAT GAG CTT CG-3′, R: 5′-CTC CGC TCT GAA CAA GGC T-3′), *EpC* (F: 5′-AGG AAG TAA TGA TGT GGC CTC C-3′, R: 5′-AGC TGG CAT CAG AAA GTA TCC ACT GTG-3′), *Ang1* (F: 5′-CAT TCT TCG CTG CCA TTT TC-3′, R: 5′-GCA CAT TGG CCA TGT TGA ATG-3′), *Ang2* (F: 5′-TTA GCA AAA AGG ATT CGG ACA ATC-3′, R: 5′-TTT TGG GGG TAG TAC TGT CAC TTA C-3′), and an unchanging control gene, *cytokeratin 4* (F: 5′-CAC ACC CCA CTG CTG ATG T-3′, R: 5′-TTC TTT TGG AAC TTT TTC GTC AA-3′). We used three methods to analyze
primer sequences for specificity of gene detection. First, the NCBI BLAST module was used to identify primer and probe sequences that specifically detected the sequence of choice. Second, amplicons generated during a PCR reaction were analyzed using the first derivative primer melting curve software (Applied Biosystems, Foster City, CA). This analysis determines the presence of amplicons on the basis of a specific melting point temperature. Third, amplicons generated were gel purified and sequenced by the Children’s Hospital Boston Core Sequencing Facility. This further confirmed the selection of the desired sequence. Quantitative analysis of gene expression was determined using a sequence detection system (ABI Prism 7700, TaqMan; and SYBR Green master mix kit [KapaBiosystem, catalog no. KK4605]). Standard curves for each gene were plotted with quantitated cDNA template during each real-time PCR reaction. Each target gene mRNA copy number was normalized to a million copies of the housekeeping gene, cyclophilin A, using the delta delta C(T) method, by comparing the C_t values of target genes in different samples, and normalized to the C_t values of an endogenous housekeeping gene cyclophilin A in these samples.

Retinal VEGF-A ELISA
Mouse VEGF-A quantitative ELISAs were used (Quantikine ELISA Kit, catalog no. MMV00; R&D Systems, Minneapolis, MN). Retinas were dissected from P17 OIR mice treated with propranolol (SC 60 mg/kg/day P12–P16) or control (n = 6 per group). Retinas were homogenized in PBS with protease inhibitor and analyzed for protein concentration by a BCA protein assay. Subsequently, VEGF-A ELISA assay was performed following the manufacturer’s instruction as described previously.15

Endothelial Cell Culture
Human retinal microvascular endothelial cells (HRMECs; Cell Systems, Kirkland, WA) were cultured in an enriched culture medium (Complete Medium; Cell Systems) and used from passages 3 to 7 for experiments. Monolayer cells were treated with varying concentrations of propranolol for 48 hours. Cells were harvested for RT-qPCR, or analyzed with Medium; Cell Systems) and used from passages 3 to 7 for experiments.

SC Injection of Propranolol Does Not Inhibit Pathologic Neovascularization
Having established that both oral gavage and IP injection of propranolol failed to improve retinopathy, we proceeded to evaluate the effect of propranolol with SC injection. Daily propranolol injections of 20 mg/kg/day from P12 to P16 again failed to protect against retinopathy. Similar levels of VO were found in the propranolol group (14.5 ± 0.7% vs. controls (13.5 ± 0.7% control; P = 0.0008, Figs. 2a, 2c). Together these data suggest that SC injection of propranolol at the standard human dose (2 mg/kg/day) does not protect against retinopathy and a higher dose of propranolol (20 mg/kg/day) may even worsen both regrowth of normal vessels (as signified by increased VO at P17) and pathologic NV in retinopathy.

Statistics
Results are presented as mean ± SEM for animal studies and mean ± SD for nonanimal studies. For all statistical analysis, a two-sample t test (or ANOVA if more than two groups of samples) was performed with values of P < 0.05 considered significant.

RESULTS

Oral Gavage of Propranolol Is Ineffective to Suppress Pathologic Neovascularization in Retinopathy
To assess the effect of propranolol in OIR, we first administered daily propranolol orally to mouse pups with induced OIR during the phase of proliferative retinopathy (P12–P16). Retinopathy development from P12 to P14 in OIR resembles stage 2 ROP in preterm infants with avascular retina and tissue hyoxia but no NV (stage 3) yet. Mice were gavaged with 2 mg/kg/day propranolol (equivalent of standard human dose for treating IH), whereas littermate control mice were fed vehicle solution. At P17 when maximal neovascular response is observed, retinas were dissected and lectin-stained to visualize retinal vasculature. The extent of VO and NV was assessed according to a standard protocol, in which the area of VO and NV were quantified in retinal flatmounts as compared with total retinal area.13,14 The propranolol-treated group showed vasoobliterated areas of 21.4 ± 1.1% compared with 19.9 ± 1.2% in the control group (P = 0.40; n = 4–6 per group) (Figs. 1a, 1b). Pathologic NV in the propranolol group was 18.1 ± 1.3%, compared with 18.4 ± 1.4% in the control group (P = 0.87; n = 4–6 per group) (Figs. 1a, 1c). There was no statistically significant difference between the propranolol-treated and control groups, which suggests that oral administration of propranolol at the given standard human dose is not effective in suppressing retinopathy.

IP Injection of Propranolol Fails to Protect against Pathologic Neovascularization
To confirm the results obtained by oral gavage, we next assessed the effect of propranolol treatment on OIR given via IP injection. After induction of retinopathy, mouse pups were injected daily with propranolol from P12 to P16, whereas littermate control mice were treated with saline injections. Compared with the control group, mice treated with 2 mg/kg/day of propranolol showed similar levels of VO (18.9 ± 0.9% in the propranolol group vs. 18.8 ± 0.9% in controls, n = 17–23 per group; P = 0.95, Figs. 2a, 2b). However, mice treated with a higher dose of propranolol (20 mg/kg/day) showed significantly increased levels of VO compared with controls (25.8 ± 1.2% in the propranolol group, n = 6; vs. 18.8 ± 0.9% in controls, n = 23; P = 0.001; Figs. 2a, 2b). With respect to pathologic NV, mice treated with propranolol at 2 mg/kg/day (18.7 ± 0.7%) showed levels similar to those of the controls (16.9 ± 0.7%, P = 0.10, Figs. 2a, 2c). However, for the higher dose of propranolol, a detrimental effect was also observed for NV. At 20 mg/kg/day of propranolol there was a significantly higher level of NV compared with that of controls (22.4 ± 0.7% propranolol vs. 16.9 ± 0.7% control; P = 0.0008, Figs. 2a, 2c). Together these data suggest that IP injection of propranolol at the standard human dose (2 mg/kg/day) does not protect against retinopathy and a higher dose of propranolol (20 mg/kg/day) may even worsen both regrowth of normal vessels (as signified by increased VO at P17) and pathologic NV in retinopathy.
results, performed with identical doses and route of intervention as reported previously, do not support a protective effect of propranolol.

**Propranolol Treatment Does Not Influence Expression of Angiogenic Factors**

Increased levels of angiogenic factors such as VEGF, erythropoietin (Epo), angiopoietin-1 (Ang1), and angiopoietin-2 (Ang2) are found in the vitreous of patients with ROP. Proangiogenic growth factors such as VEGF and Epo, and the balance between Ang1 and Ang2, can mediate pathologic vascular growth in retinopathy. To evaluate whether propranolol treatment influences the expression of angiogenic factors in OIR, retinas from control and propranolol-treated mice (SC, 60 mg/kg/day) were isolated and retinal gene expression analyzed with RT-qPCR. Compared with controls, propranolol-treated mice did not show a significant difference in the retinal expression of Vegf-A, Epo, Ang1, or Ang2 (Fig. 4d). In addition, VEGF-A protein levels analyzed with ELISA were similar between the control and propranolol groups (Fig. 4e). These results suggest that blocking β-adrenergic receptors with propranolol does not influence the expression of these angiogenic factors, which is consistent with similar levels of pathologic NV observed between the control and propranolol-treated groups (Fig. 5).

**Expression of β-Adrenergic Receptors in Retinopathy**

Because propranolol is a nonspecific β-adrenergic receptor blocker that can potentially interact with all three isoforms of
the β-adrenergic receptor, we assessed the expression of β-adrenergic receptors in OIR-exposed retinas compared with room air controls. β-Adrenergic receptor1 (ADRb1) remained unchanged in the second phase of OIR (P15 and P17) when neovessels proliferate (Fig. 5a). In contrast, β-adrenergic receptor2 (ADRb2) showed a modest upregulation at P17...
Interestingly, \( \beta \)-adrenergic receptor 3 (ADR\( \beta \)3) was upregulated dramatically (>10-fold) at P17, but unchanged at P15 (Fig. 5c). Although these receptors are modulated in retinopathy, suppression of their activity using propranolol at the given doses was not sufficient to influence the retinopathy outcome. Therefore, the regulation of \( \beta \)-adrenergic receptors in OIR may represent a retinal response to OIR, but it is unlikely to be a major cause of pathologic vessel proliferation in retinopathy development.

Low Concentrations of Propranolol Do Not Suppress Human Retinal Microvascular Endothelial Cell Proliferation

To evaluate the effect of propranolol in vitro, we treated human retinal microvascular endothelial cells (HRMECs) with various concentrations of propranolol. We found that propranolol treatment (up to 50 \( \mu \)M) did not significantly affect expression levels of either VEGF receptor 1 (VEGFR1) or VEGF receptor 2 (VEGFR2) (Figs. 6a, 6b), which suggests that propranolol treatment does not influence VEGF receptor signaling by regulating receptor expression. In addition, endothelial cell proliferation was unaffected by physiologic doses of propranolol compared with vehicle-treated cells (Fig. 6c). Although it is difficult to estimate the amount of propranolol that actually reaches the retina, a standard dose of propranolol (2 mg/kg/day), assuming equal distribution of propranolol in all tissues, will yield approximately 2 \( \mu \)M cellular concentration in the retina, a point at which EC proliferation is not suppressed (Fig. 6c). Only at high nonphysiological concentrations of propranolol (>10 \( \mu \)M) is proliferation of HMRECs significantly yet modestly suppressed (Fig. 6c). This may help to explain in part the modest decrease in vascular regrowth (i.e., increased VO) observed in the second phase of OIR (P12–P17) with propranolol (IP injection...
Propranolol fails to suppress OIR and does not affect angiogenic factors in OIR. (a) Representative images of retinal whole mounts isolated from P17 mice with induced retinopathy treated with propranolol (SC) or vehicle control three times per day from P12 to P16 (60 mg/kg/day). Retinas were stained with isolectin B4 (red) to visualize vasculature. Quantifications of VO and NV are highlighted. Scale bar: 1000 μm. (b) Quantification of VO and (c) NV as percentage of total retinal area. (d) Retinal expression of angiogenic factors (Vegf, Epo, Ang1, and Ang2) in OIR mice treated with propranolol (SC, 60 mg/kg/day) or control were quantified with RT-qPCR. (e) Protein levels of retinal VEGF from OIR mice treated with propranolol (SC, 60 mg/kg/day) or control were measured with ELISA assay. N.S., not significant.
20 mg/kg/day, Fig. 2b). Increased VO can lead to more tissue ischemia and retinal hypoxia, thus subsequent worsening of pathologic NV (Fig. 2c).

**DISCUSSION**

In this study we evaluated three routes of delivery for propranolol (oral gavage, IP injection, and SC injection) using varying doses (2–60 mg/kg/day) up to 30 times the standard human dose (2 mg/kg/day) in retinopathy. We found that none of the treatment approaches at any dose of propranolol was effective against the development of retinopathy in a mouse model of OIR. Importantly, a higher dose of IP injections of propranolol worsened retinopathy, with increases in both VO and pathologic NV. These results contradict the previous report of propranolol’s protective effects against the development of retinopathy in the same mouse model, using SC injection of propranolol (0.06–60 mg/kg/day) or IP injection (40 mg/kg/day). This discrepancy may be due to the different methods of evaluating retinopathy in OIR. The former study used fluorescent angiography to assess the extent of pathologic vessels in retinopathy and a nonstandard scoring method of quantification. Since a pathologic neovascular tuft usually does

**Figure 5.** Retinal expression of three β-adrenergic receptors in OIR: (a) β-adrenergic receptor 1 (ADRβ1), (b) β-adrenergic receptor 2 (ADRβ2), and (c) β-adrenergic receptor 3 (ADRβ3). Total retinal RNA was isolated from P15 and P17 mice with induced OIR or control mice raised in room air. Gene expression was measured with RT-qPCR and normalized to housekeeping gene cyclophilin A expression.

**Figure 6.** Effect of propranolol on human retinal microvascular endothelial cell culture (HRMEC). (a, b) Expression of two VEGF receptors (VEGFR1 and VEGFR2) is not affected with varying concentrations of propranolol treatment (0–50 μM, 48 hours). (c) Propranolol treatment (48 hours) suppresses HRMEC proliferation at high concentrations (>10 μM) as measured by MTT assay. *P < 0.05, **P < 0.01.
not have a fully formed lumen and is often inadequately perfused. Fluorescent angiography may fail to define all pathologic vessels, compared with the standard method of staining retinal vessels in with specific endothelial markers such as isolectin or CD31. Our work also showed that in OIR, propranolol at a physiologic dose does not influence retinal expression levels of VEGF, a major angiogenic growth factor regulating pathologic vessel growth in OIR and ROP. This result is consistent with our finding of propranolol’s lack of protection in OIR. Similarly, another study showed that propranolol does not affect retinal VEGF induction in a diabetic rat model. These data again do not agree with the previous study showing that propranolol suppresses VEGF production via activation of β3-adrenergic receptor. Interestingly, the same study also presented specific localization of β3-adrenergic receptors in neovascular tufts. However, in the retina, neovessels are not considered a significant source of VEGF in retinopathy, in that VEGF is secreted mostly by neuroglial cells, which do not reside in neovascular tufts or clusters but are localized in the neurosensory layers of the retina. It is therefore unclear how VEGF expression in these glial and neuronal cells would be altered by propranolol acting specifically on β3-adrenergic receptors in EC tufts. In line with this argument, an independent study ruled out a role of β3-adrenergic receptors in OIR, since a specific inhibitor against β3-adrenergic receptors (SR59230A) failed to suppress retinopathy. This work evaluated retinopathy with standard methods of CD31 staining in retinal flatmounts, but did not reexamine the efficacy of propranolol with standard quantification methods. Together these results bring into question whether propranolol regulates retinal levels of VEGF and whether the β3-adrenergic receptor plays a role in retinopathy. Interestingly, we also found that the β3-adrenergic receptor is highly upregulated at P17 in OIR. Yet the functional role of this upregulation may not necessarily be related to pathologic angiogenesis, but may for example conversely signify a role for β3-adrenergic receptors in NV regression, which starts at P17, leading to complete regression of retinal tufts and clusters by P23 to P25.

Our in vitro results using human retinal EC culture suggests that propranolol may suppress EC proliferation, but only at very high nonphysiological concentrations. This is consistent with two previous in vitro studies showing that high concentrations of propranolol suppress EC proliferation and migration, and increase EC apoptosis. The concentrations that can produce profound effects on ECs are generally higher than the doses we used in our in vivo studies of retinopathy. Consequently, failure of propranolol protection against OIR is evidence of its inability to suppress EC proliferation at lower nonapoptotic concentrations.

Interestingly in a rat model of diabetic retinopathy, activation of β3-adrenergic receptor with the agonist isoproterenol is reported to be protective against diabetes-induced retinal damages, without affecting VEGF production. Although the disease mechanisms are different in diabetic retinopathy and OIR, these results suggest an important role of the adrenergic system in the retina as well as a potentially detrimental effect of suppressing β3-adrenergic receptor, especially considering that propranolol produced decreased electroretinogram amplitudes in normal rats.

Although propranolol has been generally well tolerated in treating hemangiomas, serious adverse effects have been reported, including hypotension, bradycardia, and potentially serious metabolic changes such as hypoglycemia. Because very premature infants are at a higher risk of hypotension and insulin resistance, propranolol treatment may further derange glucose metabolism and lipid metabolism. It is important to note that a highly lipophilic drug such as propranolol can pass the blood brain barrier and reach high concentrations in the brain. However, the roles of adrenergic system and the β3-adrenergic receptor in the brain development of the premature infants are not well known. With the reports that propranolol can cause memory loss in chicks and affects learning in rats, the administration of potent beta blockers during such a critical period of brain development in preterm infants is of great concern, particularly in those infants with relatively mild stage 2 retinopathy as recruited in the clinical trial investigating the effects of propranolol (PROP-ROP). This trial uses only oral administration of propranolol (2 mg/kg/day) until NV resolves or for a maximum of 90 days. In these infants, however, ROP at stage 2 is likely to be self-limiting and regress spontaneously without treatment. Propranolol may thus pose an unnecessary and not well-studied risk factor for ocular and/or overall development of these infants.

References

16. Sapieha P, Stahl A, Chen J, et al. 5-Lipoxygenase metabolite 4-

17. Shand DG. Pharmacokinetics of propranolol: a review. Post-

18. Sato T, Kusaka S, Shimojo H, Fujikado T. Simultaneous analyses

19. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of

20. Sonmez K, Drenser KA, Capone A Jr, Trese MT. Vitreous levels

21. Sato T, Shima C, Kusaka S. Vitreous levels of angiopoietin-1 and

22. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal

23. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin

24. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP,

25. Zheng Z, Chen H, Xu X, Li C, Gu Q. Effects of angiotensin-


27. Pierce EA, Foley ED, Smith LE. Regulation of vascular


30. Steinle JJ, Booiz GW, Meininger CJ, Day JN, Granger HJ. Beta 3-

31. Jiang Y, Walker RJ, Kern TS, Steinle JJ. Application of

32. Jiang Y, Steinle JJ. Systemic propranolol reduces b-wave

33. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for

34. Bonifazi E, Acquafredda A, Milano A, Montagna O, Laforgia N.

35. Dempsey EM, Barrington KJ. Evaluation and treatment of

36. Mitanchez-Mokhtari D, Lahlou N, Kieffer F, Magny JF, Roger M,

37. Fonseca VA. Effects of beta-blockers on glucose and lipid


39. Gibbs ME, Hutchinson DS, Summers RJ. Noradrenaline release

40. Wilson DA, Sullivan RM. Olfactory associative conditioning in

Propranolol Inhibition of β-Adrenergic Receptor 2977

18. Sato T, Kusaka S, Shimojo H, Fujikado T. Simultaneous analyses

19. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of

20. Sonmez K, Drenser KA, Capone A Jr, Trese MT. Vitreous levels

21. Sato T, Shima C, Kusaka S. Vitreous levels of angiopoietin-1 and

22. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal

23. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin

24. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP,

25. Zheng Z, Chen H, Xu X, Li C, Gu Q. Effects of angiotensin-


27. Pierce EA, Foley ED, Smith LE. Regulation of vascular


30. Steinle JJ, Booiz GW, Meininger CJ, Day JN, Granger HJ. Beta 3-

31. Jiang Y, Walker RJ, Kern TS, Steinle JJ. Application of

32. Jiang Y, Steinle JJ. Systemic propranolol reduces b-wave

33. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for

34. Bonifazi E, Acquafredda A, Milano A, Montagna O, Laforgia N.

35. Dempsey EM, Barrington KJ. Evaluation and treatment of

36. Mitanchez-Mokhtari D, Lahlou N, Kieffer F, Magny JF, Roger M,

37. Fonseca VA. Effects of beta-blockers on glucose and lipid


39. Gibbs ME, Hutchinson DS, Summers RJ. Noradrenaline release

40. Wilson DA, Sullivan RM. Olfactory associative conditioning in

Propranolol Inhibition of β-Adrenergic Receptor 2977